CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Autolus data show leukemia responses deepen beyond first month after obe-cel treatment

By Public Technologies
  • Autolus Therapeutics will present clinical updates at the American Society of Hematology meeting, December 12-15, 2026, in New Orleans.
  • Obe-cel responses deepened beyond the first month in relapsed or refractory adult B-cell leukemia; delayed responders had outcomes comparable to early responders.
  • Initial phase 1 ALARIC results showed complete blood responses in patients receiving D8 CAR-T for relapsed or refractory AL amyloidosis.
  • Treatment was well tolerated, with encouraging improvements in organ function.
  • A separate analysis supported a commercially available test for monitoring obe-cel levels in clinical practice.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040915PRIMZONEFULLFEED9870030) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk